Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals
Y Hashimoto, M Hamaguchi, T Fukuda, A Ohbora… - Endocrine, 2017 - Springer
Y Hashimoto, M Hamaguchi, T Fukuda, A Ohbora, T Kojima, M Fukui
Endocrine, 2017•SpringerPurpose Recent studies identified that metabolically abnormal non-obese phenotype is a
risk factor for cardiovascular diseases. However, little is known about risk factor for
progression from metabolically healthy non-overweight to metabolically abnormal
phenotype. We hypothesized that fatty liver had a clinical impact on progression from
metabolically healthy non-overweight to metabolically abnormal phenotype. Methods In this
retrospective cohort study, 14,093 Japanese (7557 men and 6736 women), who received …
risk factor for cardiovascular diseases. However, little is known about risk factor for
progression from metabolically healthy non-overweight to metabolically abnormal
phenotype. We hypothesized that fatty liver had a clinical impact on progression from
metabolically healthy non-overweight to metabolically abnormal phenotype. Methods In this
retrospective cohort study, 14,093 Japanese (7557 men and 6736 women), who received …
Purpose
Recent studies identified that metabolically abnormal non-obese phenotype is a risk factor for cardiovascular diseases. However, little is known about risk factor for progression from metabolically healthy non-overweight to metabolically abnormal phenotype. We hypothesized that fatty liver had a clinical impact on progression from metabolically healthy non-overweight to metabolically abnormal phenotype.
Methods
In this retrospective cohort study, 14,093 Japanese (7557 men and 6736 women), who received the health-checkup program from 2004 to 2012, were enrolled. Overweight and obesity were defined as body mass index 23.0–25.0 and ≥25.0 kg/m2. Four metabolic factors (impaired fasting glucose, hypertension, hypertriglyceridemia and low high density lipoprotein-cholesterol concentration) were used for definition of metabolically healthy (less than two factors) or metabolically abnormal (two or more). We divided the participants into three groups: metabolically healthy non-overweight (9755 individuals, men/women = 4290/5465), metabolically healthy overweight (2547 individuals, 1800/747) and metabolically healthy obesity (1791 individuals, 1267/524). Fatty liver was diagnosed by ultrasonography.
Results
Over the median follow-up period of 5.3 years, 873 metabolically healthy non-overweight, 512 metabolically healthy overweight and 536 metabolically healthy obesity individuals progressed to metabolically abnormal. The adjusted hazard risks of fatty liver on progression were 1.49 (95% confidence interval 1.20–1.83, p = 0.005) in metabolically healthy non-overweight, 1.37 (1.12–1.66, p = 0.002) in metabolically healthy overweight and 1.38 (1.15–1.66, p < 0.001) in metabolically healthy obesity, after adjusting for age, sex, alcohol, smoking, exercise, impaired fasting glucose, hypertension, hypertriglyceridemia, low high density lipoprotein-cholesterol concentration, and abdominal obesity.
Conclusions
Fatty liver is an independent risk factor for progression from metabolically healthy status to metabolically abnormal phenotype, even in non-overweight individuals.
Springer
